Cancer Research The Future of Cancer Research: Science and Patient Impact  AACR Conference on Molecular Diagnostics - 2008
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 40, 2977-2978, August 1, 1980]
© 1980 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by von Kleist, S. U.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by von Kleist, S. U.

Diagnostic Significance of Tumor Markers1

Sabine U. von Kleist2

Institut fur Immunobiologie der Universitat Freiburg, Forschergruppe Tumorimmunologie, Freiburg, Germany

Progress in the immunological detection of malignant tumors has been delayed by two major obstacles: (a) the lack of true cancer specificity of the known tumor-marker substances; and (b) the lack of a close relationship between the concentration and/or first appearance of the marker antigens and the malignant disease, especially at its early stage.

An additional, important, and complicating factor implicating the specificity of the reactions of the test substances is the existence of immunological cross-reactions.

Until recently, only two approaches have been pursued to resolve this difficulty of cross-reactivity, both concerned with the antigen.

Now there is a third way, namely, the production of monoclonal antibodies. The poor correlation between the stage of the neoplastic disease and the level of circulating tumor markers, e.g., carcinoembryonic antigen, may be explained on a histological basis, or by inherent differences in the carcinoembryonic antigen molecule of different tumor sources. Few studies are available dealing with these problems.

1 Presented at the UICC Workshop on Radioimmunodetection of Cancer, July 19 to 21, 1979, Lexington, Ky. Dedicated to Prof. W. Sandritter for his 60th birthday.

2 To whom requests for reprints should be addressed.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1980 by the American Association for Cancer Research.